LongeVC founding and managing partner Sergey Jakimov is featured in CURE Magazine's roundup of eight venture funds backing rare disease startups in 2026, sharing his perspective on why this segment represents one of the most scientifically rigorous and capital-efficient opportunities in early-stage biotech.
Sergey highlights that rare disease research forces a level of mechanistic precision that most programs never reach: patient populations are defined, regulatory pathways are structured, and the biological insights unlocked through this work have a proven track record of translating into broader healthspan applications.
Read the full article here.
Sergey highlights that rare disease research forces a level of mechanistic precision that most programs never reach: patient populations are defined, regulatory pathways are structured, and the biological insights unlocked through this work have a proven track record of translating into broader healthspan applications.
Read the full article here.